問卷

TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

郭雨萱
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

78Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2024-06-01 - 2030-12-31

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2017-08-10 - 2021-06-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Terminated12Sites

2019-04-01 - 2027-11-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2019-11-01 - 2026-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-03-01 - 2032-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2020-07-01 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-08-31 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2020-10-15 - 2027-09-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-01-01 - 2028-11-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites